Alpine Immune Sciences, Inc.

NasdaqGM:ALPN Stock Report

Market Cap: US$4.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Alpine Immune Sciences Management

Management criteria checks 3/4

Alpine Immune Sciences' CEO is Mitch Gold, appointed in Jun 2016, has a tenure of 7.92 years. total yearly compensation is $2.92M, comprised of 20.5% salary and 79.5% bonuses, including company stock and options. directly owns 0.019% of the company’s shares, worth $860.60K. The average tenure of the management team and the board of directors is 4.3 years and 6.1 years respectively.

Key information

Mitch Gold

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage20.51%
CEO tenure7.9yrs
CEO ownership0.02%
Management average tenure4.3yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

Seeking Alpha • Apr 11

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Summary Vertex Pharmaceuticals Incorporated is acquiring Alpine Immune Sciences, Inc. for $4.9 billion in cash to obtain the use of povetacicept for IgAN and other kidney disorders. Positive results of povetacicept for treatment of patients with IgAN were first revealed at ASN Kidney Week In November 2023, with additional positive data just released the other day. Povetacicept is also being explored in RUBY-4 study targeting patients with autoimmune cytopenias; Data from this study will be released at a medical meeting in the 1st half of 2024. A phase 2 trial initiation, using povetacicept for the treatment of patients with systemic lupus erythematosus, is expected in the 2nd half of 2024. Read the full article on Seeking Alpha
Analysis Article • Mar 21

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) investors will be delighted, with the company turning in some strong...
Analysis Article • Mar 20

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Alpine...
Seeking Alpha • Mar 07

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Summary Alpine Immune Sciences has discarded two drug candidates since joining the Nasdaq in 2027, but its stock price has risen >200% in six months owing to its latest lead candidate. Povetacicept has shown promising results in a Phase 2 study for the treatment of IgA nephropathy, with significant reductions in proteinuria and disease-related biomarkers. The market potential for povetacicept in the IgA nephropathy indication alone is estimated to be worth billions of dollars, making it a potentially lucrative asset for Alpine. There's plenty of competition in the IgAN space, however, including two recently approved drugs and two pipeline assets with the same MoA as povetacicept. These assets belong to Vera Therapeutics and Novartis, and it's difficult to pick a winning candidate, albeit Alpine's is the least advanced. As such, I'm not sure the company fully justifies its $2.5bn market cap - I'm on the sidelines until more data is shared. Read the full article on Seeking Alpha
Analysis Article • Feb 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Despite an already strong run, Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shares have been powering on, with a gain...
Analysis Article • Dec 19

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Despite an already strong run, Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shares have been powering on, with a gain...
Analysis Article • Sep 23

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 11

Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

With a median price-to-sales (or "P/S") ratio of close to 11.6x in the Biotechs industry in the United States, you...
Analysis Article • Dec 12

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Sep 20

Alpine Immune Sciences drops 13% after hours on $100M stock offering

Alpine Immune Sciences (NASDAQ:ALPN) stock dropped 13% after the bell on Tuesday after the firm announced an underwritten public offering of $100M of shares and pre-funded warrants to buy stock. Underwriters will be granted an option for 30 days to buy up to an additional $15M of shares at the offering price. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms.
Analysis Article • Aug 09

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Apr 25

Alpine: Rest Before Rallying Again

Implementing an appropriate strategy would capture the most profits. One such strategy is diversification. A promising stock for your portfolio to diversify is Alpine Immune Science. As a rising leader in immuno-oncology, Alpine has great medicines and has thus been able to secure three interesting partnerships. Despite not having much further catalyst this year, the company is set to release data of a Phase 1 trial studying ALPN303 by mid-year.
Analysis Article • Apr 12

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Sep 18

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Aug 18

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Celebrations may be in order for Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shareholders, with the analysts...

CEO Compensation Analysis

How has Mitch Gold's remuneration changed compared to Alpine Immune Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$3mUS$599k

-US$32m

Sep 30 2023n/an/a

-US$57m

Jun 30 2023n/an/a

-US$59m

Mar 31 2023n/an/a

-US$64m

Dec 31 2022US$3mUS$544k

-US$58m

Sep 30 2022n/an/a

-US$54m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$47m

Dec 31 2021US$3mUS$523k

-US$50m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$33m

Dec 31 2020US$1mUS$500k

-US$28m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$33m

Mar 31 2020n/an/a

-US$35m

Dec 31 2019US$2mUS$485k

-US$42m

Sep 30 2019n/an/a

-US$47m

Jun 30 2019n/an/a

-US$48m

Mar 31 2019n/an/a

-US$44m

Dec 31 2018US$1mUS$400k

-US$36m

Sep 30 2018n/an/a

-US$30m

Jun 30 2018n/an/a

-US$15m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$2mUS$300k

-US$8m

Compensation vs Market: Mitch's total compensation ($USD2.92M) is below average for companies of similar size in the US market ($USD6.70M).

Compensation vs Earnings: Mitch's compensation has increased whilst the company is unprofitable.

CEO

Mitch Gold (55 yo)

7.9yrs
Tenure
US$2,921,224
Compensation

Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the...

Leadership Team

NamePositionTenureCompensationOwnership
Mitchell Gold
Executive Chairman & CEO7.9yrsUS$2.92m0.019%
$ 860.6k
Stanford Peng
President and Head of Research & Development5.1yrsUS$1.75m0.43%
$ 19.2m
Paul Rickey
Senior VP7.1yrsUS$1.28mno data
Ulrich Fuhs
VP of Finance & Chief Accounting Officerless than a yearno data0.044%
$ 2.0m
M. Yi
Chief Technology Officerless than a yearno datano data
Michelle Greenblatt
Director of Investor Relations & Corporate Communicationsno datano datano data
Remy Durand
Chief Business Officer4.3yrsno data0.15%
$ 6.6m
Andrew Sandler
Chief Medical Officer1.8yrsno datano data
4.3yrs
Average Tenure
52yo
Average Age

Experienced Management: ALPN's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mitchell Gold
Executive Chairman & CEO9.3yrsUS$2.92m0.019%
$ 860.6k
Robert Conway
Independent Director6.8yrsUS$110.21k0.073%
$ 3.2m
James Topper
Independent Director7.9yrsUS$101.46k0%
$ 0
Peter Thompson
Independent Director7.9yrsUS$103.96k0%
$ 0
Rafi Ahmed
Member of Scientific Advisory Board5.5yrsno datano data
Xiangmin Cui
Independent Director5.3yrsUS$100.21k0%
$ 0
Andrew Scharenberg
Scientific Advisory Board Chairmanno datano datano data
Christopher Peetz
Independent Director6.1yrsUS$98.96k0.0028%
$ 123.5k
John Thompson
Member of Scientific Advisory Board5.5yrsno datano data
Manish Butte
Member of Scientific Advisory Boardno datano datano data
Paul Tumeh
Member of Scientific Advisory Boardno datano datano data
James Welsh
Member of Scientific Advisory Board5.5yrsno datano data
6.1yrs
Average Tenure
58yo
Average Age

Experienced Board: ALPN's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/21 09:22
End of Day Share Price 2024/05/17 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alpine Immune Sciences, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gao Yi ChenBerenberg
Vamil DivanGuggenheim Securities, LLC
Joseph PantginisH.C. Wainwright & Co.